Genezen and InterAct Therapeutics Partner to Advance AAV8-based Gene Therapy for Liver-Dominant Metastatic Breast Cancer
“Genezen was built to help innovators translate promising science into therapies that can make a meaningful difference for patients,” said Steve Favaloro, Chairman and Chief Executive Officer of Genezen. “We are proud to bring our deep AAV development and manufacturing expertise to this partnership and work alongside InterAct Therapeutics to help move this program forward and make an impact in the oncology space. Collaborations like this embody what drives our team every day: scientific excellence, urgency for patients and a solutions-driven commitment to our partners as we work together to bring the next generation of therapies to life.”
Share:
More News
“Identifying recurrence of colorectal cancer before it becomes clinically apparent, when it is potentially much easier to treat, is one of the central challenges in developing breakthrough therapies that help to answer unmet medical needs for this setting,” said Philippe P. Calais, PharmD, Ph.D., chairman and CEO, TransCode Therapeutics. “Leveraging
“The improvement in progression-free survival is a defining moment for RYZ101 and for the patients we built this program around — people with advanced GEP-NETs whose cancer has progressed after Lu177-based therapy and who have few remaining options,” said Amreen Husain, MD, chief medical officer of RayzeBio. “This is the
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated, “The FDA’s decision to grant Fast Track Designation just nine days after submission is an encouraging milestone for opamtistomig and our first-line BTC program. We appreciate the FDA’s engagement and its recommendation to initiate discussions on the U.S. registration strategy
“PI3Kα is one of the most important, well-validated, and heavily pursued disease drivers in oncology, but its therapeutic potential has been constrained by wild-type PI3Kα-mediated toxicity and incomplete coverage of clinically relevant mutations,” said Rob Kania, Ph.D., Chief Executive Officer of KymaThera. “Our drug design objective from the outset was